demecolcine and Li-Fraumeni-Syndrome

demecolcine has been researched along with Li-Fraumeni-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for demecolcine and Li-Fraumeni-Syndrome

ArticleYear
An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.
    Proceedings of the National Academy of Sciences of the United States of America, 1998, Apr-28, Volume: 95, Issue:9

    Although it is well-established that p53 functions as a tumor suppressor gene, certain mutations exhibit gain-of-function activities that increase oncogenic transformation. We have found a common class of p53 missense mutation that exhibits a dominant, gain-of-function activity that generates genomic instability. Fibroblasts from Li-Fraumeni syndrome heterozygotes with such mutations generate polyploid cells when exposed to spindle depolymerizing agents. Expression of such mutant alleles in normal fibroblasts yields the same phenotype. This class of dominant, gain-of-function p53 mutation (p53(RSC), relaxed spindle checkpoint allele) does not require the transcriptional activation function of p53 for this behavior. Thus p53 mutations can contribute to progression of a cancer cell not only by absence of p53 tumor suppressor activity but also by the presence of an activity that promotes genetic instability.

    Topics: Animals; Cell Cycle; Demecolcine; DNA Replication; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, Dominant; Heterozygote; Humans; Li-Fraumeni Syndrome; Mice; Mutation; S Phase; Species Specificity; Spindle Apparatus; Transcription, Genetic; Tumor Suppressor Protein p53

1998